Rybelsus Geriatric (65+) Caregiver Administration Guidance

Print or save as PDFOpens the printable medication review sheet and your print dialog. No sign-up.

Does the Rybelsus dose change at 65 or older?

The Rybelsus dosing section lists one schedule for adults: 3 mg once daily for days 1 to 30 (a dose the label says is not effective for glycemic control), 7 mg once daily for days 31 to 60, then 7 mg or 14 mg from day 61 depending on whether more glycemic control is needed [1]. The label says to increase to 14 mg when additional glycemic control is needed, and it describes the stepwise schedule as a way to reduce gastrointestinal adverse reactions [1]. The dosing section gives no separate schedule by age [1].

Experience in the oldest patients is limited. In the pooled placebo-controlled trials behind the label's adverse reaction table (1,071 patients treated with semaglutide tablets, mean exposure 41.8 weeks), the mean age was 58 and 3.9% were 75 or older [1]. A larger pool of 4,116 patients from nine placebo- and active-controlled trials also had a mean age of 58, with 5% aged 75 or older [1].

Rybelsus and Ozempic tablets are both oral semaglutide but are not substitutable milligram for milligram: Ozempic tablets come as 1.5 mg, 4 mg and 9 mg, Rybelsus as 3 mg, 7 mg and 14 mg, with different starting steps [1]. When a prescription switches from one to the other, the schedule printed on the new label is the one that applies.

The morning routine the label requires

The Rybelsus label specifies one tablet each morning on an empty stomach, with no more than 4 ounces of plain water, followed by a wait of at least 30 minutes before food, beverages or other oral medicines [1]. The same section says to swallow the tablet whole, not to split, crush, chew or dissolve it in any solution, and not to take more than one tablet per day [1].

The tablets contain salcaprozate sodium (SNAC), an absorption enhancer [1]. For a caregiver, one practical approach is to measure the water into a cup ahead of time, hand over the tablet and the cup together, and hold the rest of the morning medicines until the 30 minutes are up.

Other oral medicines and the 30-minute window

Rybelsus delays gastric emptying and can change how other oral drugs are absorbed, so the label advises increased clinical or laboratory monitoring when it is taken with oral drugs that have a narrow therapeutic index or that need clinical monitoring [1].

Levothyroxine is the clearest example: its exposure increased 33% when it was given with semaglutide tablets in an interaction study [1]. That study found no clinically significant effect on warfarin [1].

What happens when a morning goes wrong

The label gives one instruction for a missed dose: skip it and take the next dose the following day [1]. It also says not to take more than one tablet per day, so a missed morning is not made up with a second tablet later [1].

Low blood sugar risk when insulin or a sulfonylurea is also taken

Semaglutide stimulates insulin release in the presence of elevated blood glucose concentrations [1]. The label warns that hypoglycemia risk increases when Rybelsus is used with insulin or an insulin secretagogue such as a sulfonylurea, including severe hypoglycemia, and that reducing the dose of the accompanying medicine may be necessary [1]. It also says people using these medicines should be told about the risk and about the signs and symptoms of low blood sugar [1].

In the 52-week insulin add-on trial, glucose below 54 mg/dL occurred in 32% of placebo-treated patients, 26% of those on Rybelsus 7 mg and 30% of those on 14 mg [1].

Nausea, vomiting and dehydration

In the pooled placebo-controlled trials, nausea occurred in 20% on 14 mg, 11% on 7 mg and 6% on placebo; diarrhea in 10%, 9% and 4%; vomiting in 8%, 6% and 3%; constipation in 5%, 6% and 2% [1]. Any gastrointestinal reaction occurred in 41% on 14 mg, 32% on 7 mg and 21% on placebo, and severe reactions in 2%, 0.6% and 0.3% [1]. Treatment was stopped for gastrointestinal reasons by 8% on 14 mg, 4% on 7 mg and 1% on placebo [1].

For an older adult the consequence that matters is fluid loss. The label warns about acute kidney injury from volume depletion, notes that most reported cases followed nausea, vomiting or diarrhea, and says to monitor renal function in patients with reactions that could lead to volume depletion, especially during starting and dose increases [1]. The label also says Rybelsus is not recommended in patients with severe gastroparesis [1].

Other label warnings caregivers may see

• Pancreatitis. Watch for persistent or severe abdominal pain, sometimes spreading to the back, with or without nausea or vomiting. The label says to discontinue Rybelsus if pancreatitis is suspected [1].
• Gallbladder disease. The label says gallbladder studies are indicated if gallstones or cholecystitis are suspected [1].
• Serious allergic reactions. Anaphylaxis and angioedema have been reported; the label says to discontinue Rybelsus if a hypersensitivity reaction occurs and monitor until signs and symptoms resolve [1].
• Thyroid C-cell tumors. The boxed warning lists a neck mass, difficulty swallowing, shortness of breath and persistent hoarseness as symptoms to report, and Rybelsus is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1].
• Eye changes. The label says patients with a history of diabetic retinopathy should be monitored for progression; diabetic retinopathy reactions were reported in 4.2% of patients on semaglutide tablets versus 3.8% on comparator in the pooled glycemic control trials [1].
• Planned surgery or sedation. Pulmonary aspiration has been reported with GLP-1 receptor agonists during general anesthesia or deep sedation, and the label tells patients to inform their healthcare providers of any planned surgery or procedure [1].

Swallowing problems

The label says to swallow the tablet whole and not to split, crush, chew or dissolve it in any solution [1]. The label describes no other way to give the dose, so crushing or dissolving the tablet is not an option for a person who has difficulty swallowing.